Meyka AI API is live for developers.Start building.
Advertisement
Royalty Pharma plc

Royalty Pharma plc (RPRX) Stock Overview

Explore Royalty Pharma plc’s financial performance, market position, analyst ratings, and future outlook.

RPRX●NASDAQ
HealthcareBiotechnology
$55.87
$0.85(1.54%)
U.S. Market opens in 54h 41m
Advertisement

Royalty Pharma plc (RPRX)

Meyka AI Score

Z

Key Financials

Market Cap24B
P/E Ratio29.08
EPS (TTM)$1.90
ROE0.13%
Fundamental Analysis

AI Price Forecasts

1 Month$47.41
3 Months$47.21
1 Year Target$50.45

RPRX Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Royalty Pharma plc (RPRX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 68.32, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $50.45.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 29.08 and a market capitalization of 24B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
1.54%
5-Day Change
2.55%
1-Month Change
10.77%
3-Month Change
22.31%
6-Month Change
40.62%
Year-to-Date (YTD) Change
44.59%
1-Year Change
65.54%
3-Year Change
67.73%
5-Year Change
20.25%
All-Time (Max) Change
25.55%

Contact Information

https://www.royaltypharma.com
212 883 0200
110 East 59th Street, New York City, NY, 10022

Company Facts

75 Employees
IPO DateJun 16, 2020
CountryUS
Actively Trading

Frequently Asked Questions